According to the agreement, Lupin s subsidiary in the Philippines, Multicare Pharmaceuticals, would seek marketing clearance and will be responsible for the biosimilars distribution and commercialization if authorized.
This agreement enhances Multicare s oncology, rheumatology, gastroenterology, and ophthalmology, portfolio, which currently consists of three biosimilar candidates and over 50 generic medicines.
Uniindia: Mumbai, Sep 7 (UNI) Pharma major Lupin on Wednesday said it has signed an exclusive license and supply agreement to commercialize five of Alvotech’s proposed biosimilars in the Philippines with DKSH, a leading partner for healthcare companies<br /
According to the agreement, Lupin s subsidiary in the Philippines, Multicare Pharmaceuticals, would seek marketing clearance and will be responsible for the biosimilars distribution and commercialization if authorized.